Eric Ostertag, Poseida CEO

Take­da en­lists Po­sei­da in $3.6B+ non­vi­ral gene ther­a­py deal, though da­ta re­main years away from hu­man stud­ies

Take­da has been be­hind oth­er ma­jor play­ers in terms of cell and gene ther­a­py de­vel­op­ment, but af­ter an­nounc­ing a col­lab­o­ra­tion with Se­lec­ta Bio­sciences last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.